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Aim: To study the influence of natural L-asparagine on the efficacy of cytostatic therapy for malignant tumors in experimental inves-
tigations. Materials and Methods: Female C57B1/6 mice weighing 18–20 g were selected for the experiments. Lewis’ lung carci-
noma (LLC) and melanoma B16 cells were used in the study. Animals were inoculated with tumor cells intramuscularly. Solution 
of L-asparagine in a volume of 0.2 ml per mouse (in appropriate doses) was administered to the animals using gastric probe, daily, for 
14 days. Cyclophosphane was administered intraperitoneally in total doses of 180 mg/kg and 90 mg/kg on days 3 and 7 after tumor 
implantation. The percentage of tumor growth inhibition was calculated and inhibition index and frequency of metastasis were assessed. 
Results: It has been shown that despite low activity of L-asparagine with regard to primary tumor, the level of metastasis inhibition 
is rather high (up to 91% depending on experimental model, therapy regimen and follow-up period). The analysis of previously obtained 
data and our studies indicate that L-asparagine derived from burdock (Arctium lappa) root has not only its own antimetastatic activ-
ity but it is also able to increase antimetastatic activity of cyclophosphane partially reducing toxic effect of cyclophosphane on the 
organism without decreasing its antitumor and antimetastatic activities. Conclusion: L-asparagine derived from burdock (Arctium 
lappa) root can be effective in the complex anticancer therapy with the use of appropriate chemotherapy doses and regimens. 
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Despite many advances in cancer treatment, tra-
ditional standard methods (surgery, radiation therapy 
and chemotherapy) do not result in a complete cure 
of cancer patients [1, 2]. Up to XVIII century, tumor 
diseases were treated mainly with herbal extracts 
and many empirically obtained data were confirmed 
by up-to-date medicine [3, 4]. Herbs are “soft” drugs, 
which combine a high biological activity with minimal 
side effects [5]. Many studies have shown that many 
herbal extracts, having moderate inhibitory effect 
on tumor development, reduce toxic effect of cyto-
static agents on blood cells and increase the functional 
activity of cells-effectors of immunity system as well 
as increase chemotherapy efficacy and protect against 
progression of metastases during surgery [6–9]. 
Studies of foreign authors and folk medicine ex-
perience in the use of extracts from burdock (Arctium 
lappa) for cancer treatment are of great interest. Bur-
dock seeds contain arctiin and arctigenin, which have 
anticancer effects. Cytotoxicity of these compounds 
has been proven on cell cultures and inoculated tu-
mors [10–12]. Arctigenin shows cytotoxicity in 100% 
of cases during oxygen-glucose deprivation in tu-
mor cells. The antiproliferative activity of glycosides 
is caused by apoptosis induction [13, 14]. Extracts 
from burdock leaves and roots are used in medicine 
as agents having diuretic, diaphoretic, blood purifying 
and anti-inflammatory effects. Antineoplastic effects 
of ethanol and dichloromethane extracts of burdock 
roots have been proved in experimental studies [15]. 
Apoptosis is an important component in the mecha-
nism of some antitumor agents. It is known that as-
paragine can be inductor of apoptosis in nervous tissue 
[16]. We have found that the concentrated juice ob-
tained from fresh burdock roots has not only cytostatic 
but also apoptosis-induced activity. The burdock root 
contains up to 10.1% of free amino  acids, maximum 
amount of asparagine (6.4% in terms of raw mate-
rial and up to 50.0% in terms of the amount of amino 
acids) [17]. 
Thus, it seems rather logical and interesting 
to study antitumor activity of L-asparagine as one 
of the main components included into the composition 
of the studied agents derived from the burdock root.
MATERIALS AND METHODS
Female C57B1/6 mice weighing 18–20 g were 
obtained from the Pharmacology Research Institute 
in Tomsk, Russia. Research was conducted in ac-
cordance with the principles set out in the Guide for 
the Care and Use of Laboratory Animals (Moscow 
Breeding Nursery, Russian Acad. Med. Sci.). 
Tumor strains. Lewis lung carcinoma (LLC) and 
melanoma B16 cells were used in the study. Strains 
obtained from the Russian Cancer Research Center 
(Russia) are highly adequate models for studying 
anti-tumor effect of biologic reaction modifiers of plant 
origin. Animals were inoculated with tumor cells intra-
muscularly at the doses of 1×106 (LLC) and 5 ×106 (B16) 
tumor cells per mouse. 
Agents. Natural L-asparagine (Tomsk). The agent 
was dissolved in warm distilled water. The obtained so-
lution in a volume of 0.2 ml per mouse (at doses of 100, 
250 and 500 mg/kg was administered to the animals 
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using gastric probe in therapeutic regimen (48 h after 
tumor implantation) daily, for 14 days.
Cyclophosphane. Cyclophosphane (Ministry 
of Medical Industry, Russia) was used in mono-and 
combined therapy for experimental tumors. Cyclo-
phosphane was administered intraperitoneally at the 
total doses of 180 mg/kg and 90 mg/kg on days 3 and 
7 after tumor implantation. 
Changes in tumor growth were assessed by mea-
suring the tumor volume according to the Shrek for-
mula: V = A × B × C, where A, B, and C are orthogonally 
related tumor sizes.
Percentage of tumor growth inhibition was cal-
culated by the formula: TGI% = [(Vc-Ve/Vc] × 100%, 
where TGI% is a coefficient of tumor growth inhibition; 
Vc is the average tumor volume in the control group 
of animals; Ve is the average tumor volume in experi-
mental group of animals. 
Index of metastasis inhibition. Metastatic spread 
into lungs was evaluated on days 10 and 20 after tumor 
inoculation. Mice were killed by cervical dislocation, 
and their lungs examined. Index of metastatic inhibition 
characterized the extent of metastatic involvement. 
It was calculated by the formula: IMI = (Ac × Bc)-
(A × B)/(Ac × Bc) × 100%, where Ac and A are the 
numbers of animals with metastases in the control 
and experimental groups; Bc and B are the average 
numbers of metastases in animals of the control and 
experimental groups. 
Frequency of tumor metastasis is the percent 
of animals with metastases with respect to the overall 
number of animals in the group. 
Statistical analysis of results was carried out using 
STATISTICA 6.0 software. Comparison between the 
groups was made by nonparametric Mann — Whitney 
test. 
RESULTS AND DISCUSSION
Influence of the combination therapy with 
L-asparagine and cyclophosphane on the growth 
of Lewis lung carcinoma. The ability of amino acid 
of L-asparagine to inhibit tumor growth and modulate 
cytostatic therapy for experimental malignant tumors 
was studied on mice with hematogenous metastasis 
of Lewis’s lung carcinoma. This model is suitable 
for studying anti-tumor and antimetastatic activities 
of agents. Double injection of cyclophospane with 
a 96-h interval is one of the standard chemotherapy 
regimens in therapy of experimental tumors, in par-
ticular, LLC [18]. We injected cyclophosphane intra-
peritoneally in total doses of 180 mg/kg or 90 mg/
kg on days 3 and 7 after tumor implantation. Therapy 
for LLC with L-asparagine at a dose of 250 mg/kg ad-
ministered alone resulted in insignificant antineoplastic 
activity of this agent at late stages of oncogenesis 
(up to 21.5% on day 20). Cyclophosphane at a dose 
of 180 mg/kg led to statistically significant inhibition 
of tumor growth  ( p  < 0.05) only at early stages of the 
experiment (on day 7 and 10 with a maximum rate 
of up to 61.8% on day 10 (Table 1).) Combination 
of L-asparagine and CPH at a dose of 180 mg/kg de-
monstrated insignificant inhibition of primary tumor 
growth as compared to monotherapy with CPH. Thus, 
it has been shown that L-asparagine has not only in-
significant activity in monotherapy regimen, but it also 
has insignificant ability to enhance therapeutic effect 
of CPH with regard to primary tumor. The attempt 
to reduce the CPH dose to 90 mg/kg resulted in inef-
fective therapy. Antitumor effect of the combination 
therapy (TGI up to 21.9% on day 20) was compared 
to that of using asparagine in monotherapy regimen. 
CPH administered in the reduced dose demonstrated 
insignificant antitumor effect (on day 20, TGI was 
up to 14.9% at a dose of 90 mg/kg versus 44.7% 
at a dose of 180 mg/kg). 
Therapy with CPH at the doses of 180 mg/kg and 
90 mg/kg resulted in respectively 26.7 and 10.1-fold 
reductions in the number of metastases on day 
20 in animals with LLC, which received the combina-
tion therapy with L-asparagine and CPH compared 
to animals receiving no this combination therapy 
(Table 2). Mice treated with CPH alone at the doses 
of 180 mg/kg and 90 mg/kg demonstrated 18.8 and 
2.7-fold reductions in the number of metastases, 
respectively. It should be noted that IMI in animals 
receiving therapy with asparagine in combination with 
CPH at the doses of 180 mg/kg and 90 mg/kg was 
rather high (98.5% and 90.1%, respectively). Me-
tastases in animals treated with asparagine and CPH 
at a dose of 180 mg/kg were observed 2.6 times more 
frequently than in animals receiving the reduced dose 
of cyclophosphane. LLC therapy with L-asparagine 
in combination with 180 mg/kg CPH led to insignifi-
cant weight loss of the liver and statistically significant 
weight loss of the spleen (Table 3). The data obtained 
can be indirect confirmation of reduction in toxic ef-
fect of CPH given in the combined therapy. We previ-
ously showed the reduction in mice spleen cellularity 
after CPH injection that was partially decreased after 
Table 1. Influence of L-asparagine (dose of 250 mg/kg) on the growth of Lewis lung carcinoma
Days
Groups of animals
Non 
treted
n=15
Asparagine
n=15
CPH (I)
n=15
Asparagine +CPH (I)
n=15 
CPH (II)
n=15
Asparagine+CPH (II)
n=15 
V V TGI % р V TGI % р V TGI % р V TGI % р V TGI % р
7 1.2±0.2 1.5±0.1 - 0.24 0.6±0.1 49.58 0.03 0.5±0.1 55,46 0.02 1.2±0.2 1.68 0.73 1.3±0.2 - 0.88
10 2.9±0.1 3.0±0.1 - 0.19 1.13±0.1 60.35 0.0008 1.09±0.1 61.75 0.0006 3.0±0.2 - 0.6 2.6±0.2 7.72 0.37
13 4.0±0.9 4.4±0.3 - 0.67 1.4±0.2 64.4 0.01 2.5±0.2 37,37 0.18 4.7±0.5 - 0.56 3.8±0.3 4.04 0.81
17 5.7±1.2 4.7±0.5 18.71 0.39 3.2±0.3 43.36 0.042 3.8±0.2 34,27 0.2 5.9±0.7 - 0.81 5.1±0.3 11.36 0.83
20 7.0±0.9 5.5±0.8 21.45 0.25 3.9±0. 44.74 0.021 4.3±0.3 39.06 0.027 6.0±0.6 14.91 0.39 5.5±0.2 21.88 0.22
Notes: CPH (I) — dose оf 180 mg/kg; CPH (II) — dose of 90 mg/kg, V — tumor volume (cm3), TGI — tumor growth inhibition, n — number of mice.
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administration of asparagine, i.e. toxic effect of CPH 
on the organism was reduced. 
Table 2. Influence of L-asparagine (dose of 250 mg/kg) on metastatic 
spread of Lewis lung carcinoma
Groups of animals
Average number of metastases, IMI
10 day 20 day
M ± SE IMI % р M ± SE IMI % р 
Non-treated, n=15 1±0,58 - - 101.3±8.7 - -
Asparagine, n=15 1±1 50.7 0.83 66.5±4.4 34.4 0.034
CPH (I) , n=15 0±0 100.0 0.19 5.4±2.2 94.7 0.024
Asparagine + CPH (I), n=15 0.3±0.3 83.5 0.38 3.8±1.8 98.5 0.024
CPH (II), n=15 0±0 100.0 0.19 37.6±12.0 62.9 0.024
Asparagine + CPH (II), n=15 0±0 100.0 0.19 10±2.0 90.1 0.025
Notes: CPH (I) — dose оf 180 mg/kg; CPH (II) — dose of 90 mg/kg, V — tu-
mor volume (cm3), TGI — tumor growth inhibition, n — number of mice; IMI — 
index of metastasis inhibition. 
Since the combined administration of CPH and L-
asparagine more markedly inhibits metastatic spread 
nearly not influencing on the primary tumor, it can 
be suggested that in this case the immune-mediated 
inhibition of metastases but not the direct effect of CPH 
on tumor cells takes place. 
Influence of monotherapy with L-asparagine 
on the growth of melanoma B-16. A statistically sig-
nificant inhibition of melanoma-16 growth on days 10 and 
15 of the experiment was found in animals, which received 
L-asparagine at a dose of 500 mg/kg (Table 4). Similar 
results were obtained on days 8 and 15 in animals, which 
received L-asparagine at a dose of 250 mg/kg. It should 
be noted that on day 13 after tumor inoculation the rate 
of tumor growth inhibition reduced to 4–7% depending 
on the dose, then, on the day 15 the rate of tumor growth 
inhibition slightly increased to 8–11%. Tumor volumes 
of the control group animals were significantly greater than 
those of the examined animals (see Table 4). 
The study of the influence of natural L-asparagine de-
rived from burdock roots on metastatic spread of melano-
ma B-16 showed a high anti-metastatic effect of this agent 
(Table 5). A statistically significant inhibition of metastasis 
was found on days 13 and 15 of the experiment (up to 80% 
and 91%, respectively). The phenomenon of inverse rela-
tionship between the dose of the agent and antimetastatic 
effect clearly detectable on day 15 is of great interest. The 
metastatic frequency at all stages of the tumor process 
was 100% in all groups of animals. 
Studies of activity of L-asparagine derived from 
the burdock root extract using the model of LLC 
showed insignificant antitumor and antimetastatic 
activities of this agent administered alone. However, 
the combination of asparagine and CPH at a dose 
of 180 mg/kg demonstrated statistically significant 
increase in metastasis inhibition (up to 99% on day 
20 of the experiment). Similar tendency was observed 
using another experimental model (melanoma B-16). 
It was shown that asparagine used alone had insignifi-
cant antitumor activity, however, the rate of metastasis 
inhibition was extremely high (up to 91% depending 
on the therapy regimen and follow-up period). Thus, 
the analysis of previous and our study results indicate 
that natural L-asparagine derived from burdock roots 
has not only its own anti-tumor activity but it is also 
able to increase anti-tumor activity of CPH (at a total 
therapeutic dose of 180 mg/kg) partially reducing its 
toxic effect on the organism. 
Table 4. Influence of L-asparagine on the growth of melanoma B-16
Days
Groups of animals
Non-
treated 
n=15
L-asparagine (500 mg/kg), 
n=15
L-asparagine (250 mg/kg), 
n=15
V V  TGI % р V TGI % р
8 0.5±0.1 0.4±0.1 33.3 0.1 0.4±0.07 35.2 0.031
10 2.0±0.2 1.5±0.1 17.2 0.05 1.7±0.1 14.2 0.14
13 3.5±0.2 3.0±0.1 6.6 0.07 3.3±0.1 4.3 0.5
15 4.9±0.1 4.3±0.2 11.2 0.03 4.5±0.1 7.9 0.02
Notes: V — tumor volume (cm3); ITG — inhibition of tumor growth.
Table 5. Influence of L-asparagine on metastatic spread of melanoma 16
Groups of animals
Average number of metastases and IMI
13 day 15 day
M ± SE IMI % p M ± SE IMI % p
Non-treated, n=15 2.9±1.1 29.5±4.5
L-asparagine (500 mg/kg), n=15 0.6±0.3 75.0 0.02 8.5±3.4 42.0 0.03
L-asparagine (250 mg/kg), n=15 0.4±0.2 80.0 0.004 1.7±0.7 91.0 0.05
Notes: IMI — index of metastasis inhibition.
Considering previously conducted studies, it can 
be concluded that the agents derived from the burdock 
root have detectable antitumor and antimetastatic 
activities. Asparagine as one of the active components 
of these agents, therefore, can be promising for cancer 
therapy. Since these agents are used as a rule in the 
complex therapy for malignant tumors, we consider 
that further experimental studies on the influence 
of L-asparagine on chemotherapy efficacy and surgery 
are required.
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